1. A 58-year-old man with type 2 diabetes mellitus (T2DM) is started on glipizide, a sulfonylurea. Which of the following best describes the molecular mechanism by which sulfonylureas stimulate insulin release from pancreatic beta cells?
A) They activate the glucagon-like peptide-1 (GLP-1) receptor on the beta cell surface, increasing intracellular cyclic AMP and augmenting glucose-dependent insulin secretion
B) They bind the SUR1 (sulfonylurea receptor 1) regulatory subunit of the ATP-sensitive potassium (KATP) channel, stabilizing it in the closed state and depolarizing the beta cell membrane
C) They directly open voltage-gated calcium channels in the beta cell plasma membrane, bypassing the requirement for membrane depolarization
D) They inhibit the enzyme dipeptidyl peptidase-4 (DPP-4), prolonging the action of endogenous incretin hormones
E) They activate AMP-activated protein kinase (AMPK) within the beta cell, increasing the synthesis and packaging of insulin into secretory granules
ANSWER: B
Rationale:
Sulfonylureas act by binding the SUR1 regulatory subunit of the KATP channel on the pancreatic beta cell, stabilizing the channel in its closed conformation. Channel closure depolarizes the membrane, opens voltage-gated calcium channels, and triggers calcium-dependent insulin exocytosis. This is a direct pharmacological extension of the physiological glucose-sensing pathway.
Option A: Option A describes the mechanism of GLP-1 receptor agonists, not sulfonylureas; sulfonylureas do not act on the GLP-1 receptor.
Option C: Option C is incorrect because sulfonylureas do not directly open voltage-gated calcium channels; calcium entry follows membrane depolarization produced by KATP channel closure.
Option D: Option D describes DPP-4 inhibitors, an entirely separate drug class.
Option E: Option E misattributes the AMPK pathway, which is central to metformin action in hepatocytes, to the sulfonylurea mechanism in beta cells.
2. A 72-year-old woman taking glyburide skips breakfast and lunch because of a poor appetite during a viral illness. She develops symptomatic hypoglycemia in the early afternoon. Which property of sulfonylureas best explains why hypoglycemia is the principal adverse effect of this drug class?
A) Sulfonylureas inhibit hepatic gluconeogenesis, removing the liver's ability to raise blood glucose during fasting
B) Sulfonylureas block renal glucose reabsorption, causing continuous urinary glucose loss regardless of intake
C) Sulfonylureas increase peripheral insulin sensitivity so profoundly that even basal insulin levels produce hypoglycemia
D) Sulfonylureas stimulate insulin secretion in a glucose-independent manner, so insulin release continues even when plasma glucose is low
E) Sulfonylureas delay gastric emptying, causing a mismatch between carbohydrate absorption and the timing of endogenous insulin release
ANSWER: D
Rationale:
The defining feature of sulfonylurea pharmacology is glucose-independent stimulation of insulin secretion: by closing the KATP channel directly, they drive insulin release regardless of the ambient glucose concentration. When a meal is skipped, insulin secretion continues unopposed by glucose intake, producing hypoglycemia. This is the mechanistic basis of their primary risk.
Option A: Option A describes a metformin-like effect on hepatic glucose output, not the sulfonylurea mechanism.
Option B: Option B describes sodium-glucose cotransporter-2 (SGLT-2) inhibitors, which do not cause hypoglycemia by this route.
Option C: Option C is incorrect because sulfonylureas are secretagogues, not insulin sensitizers; they do not act primarily by enhancing peripheral sensitivity.
Option E: Option E describes an incretin/amylin-type effect on gastric emptying and is not the mechanism of sulfonylurea-induced hypoglycemia.
3. A 68-year-old man with chronic kidney disease (CKD) and an estimated glomerular filtration rate (eGFR) of 38 mL/min/1.73m2 requires a sulfonylurea. Which agent carries the highest risk of severe, prolonged hypoglycemia in this patient, and why?
A) Glyburide, because it is metabolized to weakly active metabolites that accumulate as renal function declines, prolonging insulin secretion
B) Glipizide, because it is inactivated entirely by the kidney and therefore reaches toxic concentrations in renal impairment
C) Glimepiride, because it is excreted unchanged in the urine and is the only sulfonylurea that bypasses hepatic metabolism
D) Tolbutamide, because its second-generation potency makes even small accumulations dangerous in CKD
E) Glipizide, because its active metabolite has three times the potency of the parent drug and accumulates in renal failure
ANSWER: A
Rationale:
Glyburide (glibenclamide) is metabolized in the liver to weakly active metabolites that are renally excreted; these metabolites accumulate as renal function declines, substantially extending the duration of insulin secretion and producing severe, prolonged hypoglycemia. It is the most dangerous sulfonylurea in CKD and the agent most consistently avoided in this population.
Option B: Option B is incorrect because glipizide is inactivated to non-active metabolites by CYP2C9 (cytochrome P450 2C9) and is the preferred agent in CKD, not a high-risk one.
Option C: Option C misstates glimepiride pharmacology; glimepiride is hepatically metabolized to an active M1 metabolite, not excreted unchanged.
Option D: Option D is incorrect because tolbutamide is a first-generation agent, not second-generation, and is not the highest-risk sulfonylurea in CKD.
Option E: Option E inverts the facts: the active metabolite description belongs to glimepiride (M1, roughly one-third potency), and glipizide is the renally safe option, not a high-risk one.
4. A 64-year-old woman with CKD stage 3 (estimated glomerular filtration rate, eGFR, 45 mL/min/1.73m2) needs a secretagogue added to her regimen. Among the sulfonylureas, which agent is preferred in this setting and for what pharmacokinetic reason?
A) Glyburide, because its renally excreted metabolites maintain a stable, predictable plasma concentration in CKD
B) Chlorpropamide, because its long half-life provides smooth once-daily glycemic control in renal impairment
C) Glipizide, because it is metabolized by CYP2C9 to inactive metabolites and does not accumulate in renal failure
D) Glimepiride, because it is the only sulfonylurea with no active metabolite of any kind
E) Tolazamide, because first-generation agents are cleared independently of renal function
ANSWER: C
Rationale:
Glipizide undergoes extensive hepatic metabolism by CYP2C9 to inactive metabolites, so it does not accumulate when renal clearance declines. This makes it the preferred sulfonylurea in CKD when a secretagogue is clinically required.
Option A: Option A is incorrect because glyburide's weakly active metabolites accumulate in CKD and produce prolonged hypoglycemia, making it the agent to avoid.
Option B: Option B is incorrect because chlorpropamide is a first-generation sulfonylurea with a very long half-life that increases hypoglycemia risk and is not preferred in renal impairment.
Option D: Option D misstates glimepiride pharmacology; glimepiride does have an active M1 metabolite (roughly one-third potency) that is renally excreted and requires dose reduction in CKD.
Option E: Option E is incorrect because first-generation agents such as tolazamide are not cleared independently of renal function and are generally avoided due to unfavorable pharmacokinetics and interaction risk.
5. Metformin is the universal first-line pharmacological therapy for T2DM in all major guidelines. Beyond glucose lowering, which feature most distinguishes metformin from other oral antidiabetic agents and supports its first-line status?
A) It produces the largest single-agent reduction in HbA1c (glycated hemoglobin) of any oral antidiabetic drug
B) It is the only oral agent that can be safely used at any level of renal function without dose adjustment
C) It reliably promotes weight loss of 5 to 10 kg in most patients, addressing obesity in T2DM
D) It is the only secretagogue that stimulates insulin release without causing hypoglycemia
E) It is the only oral antidiabetic agent with randomized trial data showing reduced cardiovascular and all-cause mortality independent of glycemic control
ANSWER: E
Rationale:
Metformin stands apart because the UKPDS (United Kingdom Prospective Diabetes Study) and its post-trial follow-up demonstrated reduced all-cause and cardiovascular mortality that was independent of glycemic control and sustained over long-term follow-up (the legacy effect). This mortality benefit, combined with weight neutrality, absence of hypoglycemia, and low cost, underpins its first-line status.
Option A: Option A is incorrect because metformin does not produce the largest HbA1c reduction of all oral agents; sulfonylureas can produce comparable or greater reductions.
Option B: Option B is incorrect because metformin is contraindicated below an eGFR of 30 mL/min/1.73m2 and requires caution at lower eGFR ranges.
Option C: Option C overstates the effect; metformin is weight-neutral or produces modest weight reduction, not 5 to 10 kg loss.
Option D: Option D is incorrect because metformin is not a secretagogue at all; it does not stimulate insulin release.
6. Which of the following is the primary and best-characterized molecular mechanism of metformin action?
A) Irreversible inhibition of pancreatic alpha-cell glucagon secretion, removing the principal counter-regulatory drive to hepatic glucose output
B) Inhibition of mitochondrial complex I (NADH:ubiquinone oxidoreductase) in hepatocytes, reducing ATP synthesis and raising the AMP/ATP ratio
C) Direct agonism at the peroxisome proliferator-activated receptor gamma (PPAR-gamma), enhancing transcription of insulin-sensitizing genes
D) Competitive inhibition of intestinal alpha-glucosidase, slowing the breakdown of complex carbohydrates in the gut lumen
E) Activation of the SUR1 subunit of the beta cell KATP channel, augmenting glucose-stimulated insulin secretion
ANSWER: B
Rationale:
The primary and best-characterized mechanism of metformin is inhibition of mitochondrial complex I (NADH:ubiquinone oxidoreductase) in hepatocytes. This reduces oxidative phosphorylation and ATP synthesis, raising the AMP/ATP ratio and activating AMP-activated protein kinase (AMPK), which suppresses hepatic gluconeogenesis.
Option A: Option A is incorrect because metformin does not act primarily by inhibiting glucagon secretion.
Option C: Option C describes the mechanism of thiazolidinediones (PPAR-gamma agonists), not metformin.
Option D: Option D describes alpha-glucosidase inhibitors such as acarbose, a separate class.
Option E: Option E describes the sulfonylurea/secretagogue mechanism, which is unrelated to metformin's action on hepatic energy metabolism.
7. A patient newly diagnosed with T2DM asks whether metformin will put her at risk of dangerously low blood sugar, as she has heard happens with some diabetes pills. Which statement best characterizes metformin's hypoglycemia risk as monotherapy?
A) Metformin does not cause hypoglycemia as monotherapy because it does not stimulate glucose-independent insulin secretion
B) Metformin frequently causes hypoglycemia because it closes the beta cell KATP channel like the sulfonylureas
C) Metformin causes hypoglycemia only in patients with normal renal function, where it is most rapidly cleared
D) Metformin causes profound hypoglycemia by directly increasing peripheral glucose uptake independent of insulin to dangerous degrees
Metformin does not cause hypoglycemia as monotherapy because it is not an insulin secretagogue; it reduces hepatic glucose output and improves insulin sensitivity without driving glucose-independent insulin release. This is a key safety advantage over sulfonylureas.
Option B: Option B is incorrect because metformin does not act on the beta cell KATP channel; that is the sulfonylurea mechanism.
Option C: Option C is incorrect because metformin monotherapy does not cause hypoglycemia regardless of renal function, and renal impairment increases accumulation rather than provoking hypoglycemia.
Option D: Option D overstates and misstates metformin's effect; while it modestly improves peripheral glucose disposal, it does not produce profound insulin-independent hypoglycemia.
Option E: Option E is incorrect because metformin does not cause hypoglycemia by depleting hepatic glycogen reserves.
8. A patient is prescribed repaglinide, a meglitinide. Which instruction best reflects the correct dosing strategy for this drug class?
A) Take one fixed dose each morning regardless of meals, since the drug has a long, steady duration of action
B) Take the dose at bedtime to suppress overnight hepatic glucose production
C) Take the dose only when fasting glucose is elevated, independent of meal timing
D) Take a dose before each main meal, and omit the dose if a meal is skipped, because the drug provides short-acting prandial insulin coverage
E) Take the dose two hours after eating to capture the late postprandial glucose peak
ANSWER: D
Rationale:
Meglitinides are short-acting prandial secretagogues with rapid on-off binding kinetics, designed to produce a brief insulin secretory burst timed to meal ingestion. The correct strategy is to dose before each main meal and to omit the dose when a meal is skipped, which avoids interprandial hypoglycemia.
Option A: Option A is incorrect because meglitinides are not long-acting once-daily agents; their short duration is the defining feature.
Option B: Option B is incorrect because bedtime dosing to suppress overnight hepatic glucose output describes a metformin- or basal-insulin-type strategy, not a prandial secretagogue.
Option C: Option C is incorrect because meglitinides target postprandial rather than fasting glucose and are dosed by meal, not by fasting glucose level.
Option E: Option E is incorrect because the dose is taken immediately before the meal to coincide with the postprandial glucose rise, not two hours afterward.
9. According to current FDA and ADA guidance, at what level of renal function is metformin contraindicated?
A) When the estimated glomerular filtration rate (eGFR) falls below 60 mL/min/1.73m2
B) When the eGFR falls below 45 mL/min/1.73m2
C) When the eGFR falls below 30 mL/min/1.73m2
D) Metformin is never contraindicated on the basis of renal function alone, only on the basis of liver disease
E) Only when the patient is anuric and requires dialysis
ANSWER: C
Rationale:
Current FDA (U.S. Food and Drug Administration) and ADA (American Diabetes Association) guidance contraindicates metformin when the eGFR falls below 30 mL/min/1.73m2. Between 30 and 45 mL/min/1.73m2, it is used with caution and reduced doses; above 45 mL/min/1.73m2 it can be used at full doses.
Option A: Option A is incorrect because metformin is not contraindicated at an eGFR of 60; full dosing is permitted well below that level.
Option B: Option B is incorrect because 30 to 45 mL/min/1.73m2 is the cautious-use range, not the contraindication threshold.
Option D: Option D is incorrect because renal function is precisely the principal determinant of the metformin contraindication, given its entirely renal clearance.
Option E: Option E is incorrect because the contraindication applies below an eGFR of 30, not only in anuric dialysis-dependent patients.
10. Tracing metformin's hepatic mechanism from cellular entry to its effect on glucose production, which sequence is correct?
A) Metformin enters hepatocytes via OCT1, inhibits complex I to raise the AMP/ATP ratio, activates AMPK, and suppresses transcription of the gluconeogenic enzymes PEPCK and G6Pase
B) Metformin enters hepatocytes via SGLT2, stimulates complex I, lowers the AMP/ATP ratio, and increases transcription of gluconeogenic enzymes
C) Metformin binds SUR1 on the hepatocyte surface, closes a potassium channel, depolarizes the cell, and triggers glucose release
D) Metformin activates PPAR-gamma in the hepatocyte nucleus, directly increasing gluconeogenesis to be metabolized later
E) Metformin enters hepatocytes via OCT1, activates complex I, and increases hepatic glucose output through enhanced oxidative phosphorylation
ANSWER: A
Rationale:
Metformin is taken up into hepatocytes by OCT1 (organic cation transporter 1), where it inhibits mitochondrial complex I. The resulting fall in ATP synthesis raises the AMP/ATP ratio, activating AMPK (AMP-activated protein kinase). AMPK inactivates the co-activator TORC2, reducing transcription of PEPCK (phosphoenolpyruvate carboxykinase) and G6Pase (glucose-6-phosphatase), the rate-limiting gluconeogenic enzymes, thereby lowering hepatic glucose output.
Option B: Option B is incorrect because metformin does not enter via SGLT2 and inhibits rather than stimulates complex I.
Option C: Option C describes the sulfonylurea/SUR1 mechanism in beta cells, not hepatocyte metformin action.
Option D: Option D is incorrect because metformin does not act through PPAR-gamma and suppresses rather than increases gluconeogenesis.
Option E: Option E inverts the mechanism: metformin inhibits complex I and reduces hepatic glucose output, rather than enhancing oxidative phosphorylation and glucose production.
11. Both repaglinide and the sulfonylureas ultimately close the beta cell KATP channel, yet repaglinide has a markedly shorter duration of action. Which difference best explains this?
A) Repaglinide acts on a completely different ion channel (a voltage-gated sodium channel) rather than the KATP channel
B) Repaglinide is administered intravenously, giving it a shorter elimination half-life than oral sulfonylureas
C) Repaglinide does not bind SUR1 at all but instead inhibits insulin-degrading enzyme, prolonging existing insulin
D) Repaglinide irreversibly alkylates SUR1, so its effect ends only when new channel protein is synthesized
E) Repaglinide binds a distinct site on SUR1 (the benzamido site) with faster association and dissociation kinetics, allowing more complete channel reopening between doses
ANSWER: E
Rationale:
Repaglinide binds a distinct site on the SUR1 subunit (the benzamido site), separate from the sulfonylurea binding site though on the same subunit. This site has faster association and dissociation kinetics, producing a shorter duration of action and more complete KATP channel reopening between doses.
Option A: Option A is incorrect because repaglinide acts on the same KATP channel through SUR1, not on a voltage-gated sodium channel.
Option B: Option B is incorrect because repaglinide is an oral agent, not intravenous.
Option C: Option C is incorrect because repaglinide does bind SUR1 and does not act by inhibiting insulin-degrading enzyme.
Option D: Option D is incorrect because repaglinide binding is rapidly reversible, which is precisely why its action is short; it does not irreversibly modify the channel.
12. A patient stabilized on repaglinide is about to be started on gemfibrozil for hypertriglyceridemia. Why is this combination contraindicated?
A) Gemfibrozil displaces repaglinide from albumin, reducing its free concentration and causing loss of glycemic control
B) Gemfibrozil induces CYP3A4, accelerating repaglinide clearance and precipitating hyperglycemia
C) Gemfibrozil inhibits CYP2C8, raising repaglinide exposure approximately eight-fold and producing severe hypoglycemia
D) Gemfibrozil and repaglinide compete for renal tubular secretion, causing repaglinide to accumulate to nephrotoxic levels
E) Gemfibrozil blocks OCT1-mediated hepatic uptake of repaglinide, preventing it from reaching its site of action
ANSWER: C
Rationale:
Gemfibrozil is a potent inhibitor of CYP2C8 (cytochrome P450 2C8), one of the enzymes that metabolizes repaglinide. Co-administration raises repaglinide AUC (area under the curve) approximately eight-fold, producing a severe hypoglycemia risk, which is why the combination is contraindicated.
Option A: Option A is incorrect because the interaction is metabolic (enzyme inhibition), not protein-binding displacement, and the effect is increased rather than decreased repaglinide exposure.
Option B: Option B inverts the direction: gemfibrozil inhibits rather than induces the relevant enzyme, raising exposure and causing hypoglycemia, not hyperglycemia.
Option D: Option D is incorrect because repaglinide is eliminated by hepatic/biliary routes with minimal renal excretion, so renal tubular competition is not the mechanism.
Option E: Option E is incorrect because gemfibrozil does not block OCT1 uptake of repaglinide; the interaction is through CYP2C8 inhibition that increases drug levels.
13. A patient with CKD who has previously experienced prolonged sulfonylurea-induced hypoglycemia requires a secretagogue. Which property of repaglinide makes it a reasonable choice in renal impairment?
A) Repaglinide is excreted unchanged by the kidney, so its dose can be titrated precisely against eGFR
B) Repaglinide is eliminated predominantly by hepatic metabolism and biliary excretion, with less than 10 percent renal excretion of unchanged drug, so it does not accumulate due to renal impairment
C) Repaglinide has no active metabolites and is removed entirely by hemodialysis, making it safe at any renal function
D) Repaglinide is not metabolized at all and is exhaled unchanged, bypassing both renal and hepatic clearance
E) Repaglinide binds plasma proteins so tightly that it is never filtered by the glomerulus, regardless of renal function
ANSWER: B
Rationale:
Repaglinide is extensively metabolized by CYP3A4 and CYP2C8 to inactive metabolites that are eliminated primarily in bile and feces, with less than 10 percent renal excretion of unchanged drug. Because elimination is predominantly hepatic/biliary, repaglinide does not accumulate as a direct consequence of renal impairment, a pharmacokinetic advantage over sulfonylureas in CKD.
Option A: Option A is incorrect because repaglinide is not excreted unchanged by the kidney; it is hepatically metabolized.
Option C: Option C is incorrect because repaglinide safety in CKD derives from its elimination route, not from dialytic removal, and the claim of total dialysis clearance is unsupported.
Option D: Option D is incorrect because repaglinide is metabolized hepatically, not exhaled.
Option E: Option E is incorrect because although repaglinide is protein-bound, its renal safety stems from hepatic/biliary elimination rather than from being unfilterable.
14. Studies in mice with liver-specific deletion of AMPK show that metformin still lowers fasting glucose, indicating an AMPK-independent hepatic mechanism. Which of the following best describes this mechanism?
A) Metformin directly phosphorylates PEPCK, inactivating it independently of any redox change
B) Metformin upregulates GLUT2 expression on hepatocytes, increasing glucose uptake into the liver
C) Metformin stimulates glycogen synthase, diverting glucose into storage rather than release
D) By inhibiting complex I, metformin raises the cytosolic NADH-to-NAD+ ratio, limiting the conversion of lactate and glycerol into gluconeogenic substrate because those steps require NAD+
E) Metformin activates glucokinase, trapping glucose as glucose-6-phosphate and preventing its export
ANSWER: D
Rationale:
The AMPK-independent mechanism arises from complex I inhibition reducing mitochondrial NADH oxidation, which raises the cytosolic NADH-to-NAD+ ratio. Because gluconeogenesis from lactate (via lactate dehydrogenase) and from glycerol (via glycerol-3-phosphate dehydrogenase) requires NAD+, the elevated NADH/NAD+ ratio limits substrate flux into gluconeogenesis even when AMPK signaling is absent.
Option A: Option A is incorrect because metformin does not directly phosphorylate PEPCK; the transcriptional effect on PEPCK is AMPK-dependent, whereas the AMPK-independent route is redox-based.
Option B: Option B is incorrect because metformin does not lower glucose by upregulating hepatic GLUT2 uptake.
Option C: Option C is incorrect because the AMPK-independent effect operates through redox limitation of gluconeogenic substrate, not through stimulation of glycogen synthase.
Option E: Option E is incorrect because glucokinase activation is not the mechanism of metformin's AMPK-independent glucose lowering.
15. Why does renal impairment increase the risk of metformin-associated lactic acidosis (MALA)?
A) Metformin is not metabolized and is excreted unchanged by the kidney via OCT2 and MATE transporters, so declining renal function causes drug and lactate accumulation
B) Metformin is hepatically metabolized to a lactic acid metabolite that the failing kidney cannot reabsorb
C) Renal impairment induces hepatic CYP enzymes that convert metformin into a directly toxic acidic species
D) Metformin is filtered but then completely reabsorbed in healthy kidneys, so only failing kidneys excrete enough to cause toxicity
E) Renal failure increases gastrointestinal absorption of metformin, raising plasma concentrations independent of clearance
ANSWER: A
Rationale:
Metformin is a hydrophilic, highly ionized molecule that is not metabolized; it is excreted unchanged by the kidney through glomerular filtration and active tubular secretion via OCT2 (organic cation transporter 2) and MATE1/MATE2-K (multidrug and toxin extrusion proteins). Because clearance is entirely renal, declining renal function causes proportional drug and lactate accumulation, the mechanistic basis of MALA.
Option B: Option B is incorrect because metformin is not hepatically metabolized to a lactic acid metabolite; it is eliminated unchanged.
Option C: Option C is incorrect because metformin is not converted by CYP enzymes into a toxic acidic species.
Option D: Option D is incorrect because metformin is not completely reabsorbed in healthy kidneys; healthy kidneys efficiently secrete and eliminate it.
Option E: Option E is incorrect because renal failure raises metformin levels through reduced clearance, not increased gastrointestinal absorption.
16. Sulfonylureas are highly protein-bound. What is the clinical consequence of this pharmacokinetic property?
A) They cannot cross cell membranes, so they require a specific uptake transporter to reach the beta cell
B) They are entirely confined to the intracellular compartment, giving them a very large volume of distribution
C) They are rapidly cleared by glomerular filtration because the bound fraction is freely filtered
D) Protein binding makes them ineffective until displaced, so they have a delayed onset of several days
E) Other highly protein-bound drugs can displace them from albumin, transiently raising free sulfonylurea concentrations and increasing hypoglycemia risk
ANSWER: E
Rationale:
Sulfonylureas are highly bound to albumin (greater than 90 percent). Co-administered drugs that are also highly protein-bound can displace them from albumin binding sites, transiently increasing the free (active) drug concentration and raising the risk of hypoglycemia. This is a clinically significant interaction.
Option A: Option A is incorrect because high protein binding does not prevent membrane crossing or mandate a specific uptake transporter to reach the beta cell.
Option B: Option B is incorrect because high protein binding keeps the drug largely in the vascular compartment, producing a small volume of distribution (approximately 0.1 to 0.15 L/kg), not a large one.
Option C: Option C is incorrect because the protein-bound fraction is not freely filtered by the glomerulus; binding actually limits filtration.
Option D: Option D is incorrect because sulfonylureas are active without requiring displacement and do not have a multi-day delayed onset.
17. Within the 2023 ADA/EASD consensus framework for T2DM, where do sulfonylureas and meglitinides fit relative to agents such as GLP-1 receptor agonists and SGLT-2 inhibitors?
A) They are the preferred agents in patients with established atherosclerotic cardiovascular disease because of proven cardiovascular benefit
B) They are not preferred on the cardiovascular, heart failure, kidney, or weight/hypoglycemia axes, but retain an important role in cost-sensitive prescribing
C) They are preferred in patients with heart failure with reduced ejection fraction because of their cardiorenal protective effects
D) They have been removed from current guidelines entirely and no longer have any recommended role
E) They are the preferred first-line backbone agent, having replaced metformin in the most recent consensus
ANSWER: B
Rationale:
In the 2023 ADA/EASD (American Diabetes Association/European Association for the Study of Diabetes) framework, agent selection is organized around comorbidity axes—atherosclerotic cardiovascular disease, heart failure, CKD, and weight/hypoglycemia—on which GLP-1 (glucagon-like peptide-1) receptor agonists and SGLT-2 (sodium-glucose cotransporter-2) inhibitors are preferred. Sulfonylureas and meglitinides are not preferred on any of those axes but retain an important role in cost-sensitive prescribing because of their low cost and established efficacy.
Option A: Option A is incorrect because secretagogues do not have proven cardiovascular benefit and are not preferred for ASCVD.
Option C: Option C is incorrect because SGLT-2 inhibitors, not secretagogues, are preferred for heart failure with reduced ejection fraction.
Option D: Option D is incorrect because these agents remain in the guidelines with a defined, if secondary, role.
Option E: Option E is incorrect because metformin remains the foundational first-line agent for most patients; secretagogues have not replaced it.
18. A patient on metformin is scheduled for a contrast-enhanced CT scan using iodinated contrast. Metformin is held at the time of the procedure and not restarted for 48 hours pending recheck of renal function. What is the rationale?
A) Iodinated contrast chemically inactivates metformin, so dosing during this window is futile
B) Contrast media compete with metformin for OCT1 hepatic uptake, blocking its glucose-lowering effect for 48 hours
C) Contrast-induced acute kidney injury can rapidly reduce eGFR, shifting the patient into a contraindicated range while high metformin concentrations remain in tissues and raising MALA risk
D) Holding metformin prevents a direct allergic cross-reaction between the biguanide and iodine
E) Metformin must be held because it causes false elevation of serum creatinine that would obscure interpretation of post-contrast renal function
ANSWER: C
Rationale:
Iodinated contrast can precipitate acute kidney injury (contrast-induced nephropathy), which can rapidly lower eGFR and move a patient from a safe to a contraindicated range while metformin remains accumulated in tissues. Because metformin clearance is entirely renal, this combination raises the risk of metformin and lactate accumulation and lactic acidosis, justifying the hold and renal recheck before restarting.
Option A: Option A is incorrect because contrast does not chemically inactivate metformin.
Option B: Option B is incorrect because the concern is renal injury and drug accumulation, not competition for hepatic OCT1 uptake.
Option D: Option D is incorrect because the issue is not an allergic cross-reaction between biguanide and iodine.
Option E: Option E is incorrect because metformin does not cause false creatinine elevation; the hold is about preventing accumulation during possible acute renal impairment.
19. A patient on long-term metformin develops a macrocytic anemia and worsening peripheral neuropathy. Which metformin-related adverse effect should be considered, and what is its mechanism?
A) Iron deficiency, because metformin chelates dietary iron in the gut lumen
B) Folate deficiency, because metformin competitively inhibits dihydrofolate reductase
C) Thiamine deficiency, because metformin blocks intestinal thiamine transporters
D) Vitamin B12 (cobalamin) deficiency, because metformin interferes with calcium-dependent ileal absorption of the vitamin B12-intrinsic factor complex
E) Vitamin D deficiency, because metformin accelerates hepatic catabolism of 25-hydroxyvitamin D
ANSWER: D
Rationale:
Long-term metformin use is a recognized cause of vitamin B12 (cobalamin) deficiency. Metformin reduces ileal absorption of the vitamin B12-intrinsic factor complex by interfering with the calcium-dependent binding of the complex to its ileal receptor. Subclinical deficiency progresses to macrocytic anemia and peripheral neuropathy that can mimic or worsen diabetic polyneuropathy, and ADA guidelines recommend periodic B12 monitoring.
Option A: Option A is incorrect because metformin does not cause iron deficiency by chelating dietary iron.
Option B: Option B is incorrect because metformin does not inhibit dihydrofolate reductase; that is the mechanism of methotrexate and trimethoprim.
Option C: Option C is incorrect because thiamine transporter blockade is not the metformin mechanism.
Option E: Option E is incorrect because metformin does not cause vitamin D deficiency through accelerated hepatic catabolism.
20. A patient adherent to metformin at an adequate dose, with confirmed therapeutic plasma concentrations, shows a disappointing HbA1c response. Which pharmacogenomic explanation is most consistent with this picture?
A) Loss-of-function variants in OCT1 (SLC22A1) reduce hepatic uptake of metformin, blunting its effect on hepatic gluconeogenesis despite adequate plasma levels
B) Gain-of-function variants in OCT2 cause the kidney to clear metformin so rapidly that hepatic exposure is never achieved
C) A CYP2C9 polymorphism accelerates metformin metabolism, lowering active drug concentrations at the liver
D) An SUR1 mutation prevents metformin from closing the beta cell KATP channel, abolishing insulin secretion
E) A MATE1 overexpression variant increases intestinal absorption of metformin, paradoxically reducing its hepatic action
ANSWER: A
Rationale:
OCT1 (organic cation transporter 1, encoded by SLC22A1) mediates hepatic uptake of metformin, the step required for it to reach its intracellular site of action. Loss-of-function OCT1 variants reduce hepatic metformin accumulation and blunt the HbA1c-lowering response even when plasma concentrations are adequate, because the drug cannot efficiently enter hepatocytes.
Option B: Option B is incorrect because the scenario specifies adequate plasma concentrations, which is inconsistent with rapid renal clearance preventing exposure, and the relevant variability is in hepatic uptake.
Option C: Option C is incorrect because metformin is not metabolized by CYP2C9; it is excreted unchanged.
Option D: Option D is incorrect because metformin does not act on the beta cell SUR1/KATP channel, so an SUR1 mutation is irrelevant to its effect.
Option E: Option E is incorrect because the clinically established pharmacogenomic determinant is reduced OCT1-mediated hepatic uptake, not a MATE1-driven increase in intestinal absorption.
21. The CAROLINA trial compared glimepiride with linagliptin (a DPP-4 inhibitor) as add-on to metformin. Which statement best summarizes its findings and their significance for sulfonylurea use?
A) Glimepiride was inferior for cardiovascular outcomes and inferior for HbA1c reduction, confirming that sulfonylureas should be abandoned
B) Glimepiride caused fewer hypoglycemic events than linagliptin while achieving greater HbA1c reduction
C) Glimepiride increased cardiovascular mortality compared with linagliptin, establishing a clear cardiovascular harm signal for second-generation sulfonylureas
D) The trial showed no difference between the agents in any outcome, providing no useful guidance
E) Glimepiride was non-inferior for cardiovascular outcomes and produced greater HbA1c reduction, but with significantly higher hypoglycemia rates, providing contemporary evidence for both sulfonylurea efficacy and hypoglycemia liability
ANSWER: E
Rationale:
CAROLINA (CARdiovascular Outcome trial of LINAgliptin versus glimepiride) demonstrated non-inferior cardiovascular outcomes for glimepiride versus linagliptin, confirmed glimepiride's superior HbA1c reduction, but showed significantly higher hypoglycemia rates with glimepiride. This provides a contemporary evidence basis for both the efficacy and the hypoglycemia liability of sulfonylureas in the metformin-combination context.
Option A: Option A is incorrect because glimepiride was not inferior for cardiovascular outcomes and produced greater, not lesser, HbA1c reduction.
Option B: Option B inverts the hypoglycemia finding; glimepiride caused more, not fewer, hypoglycemic events.
Option C: Option C is incorrect because the trial established cardiovascular non-inferiority, not a harm signal.
Option D: Option D is incorrect because the trial did show meaningful differences (HbA1c and hypoglycemia) and provided clinically useful guidance.
22. A patient has predominantly postprandial hyperglycemia with relatively preserved fasting glucose, and the clinician is considering nateglinide. Which description of nateglinide is correct?
A) It is a sulfonylurea with the longest duration of action, providing 24-hour basal coverage from a single dose
B) It binds SUR1 irreversibly, producing the most sustained insulin secretion of any secretagogue
C) It is a phenylalanine derivative with the fastest dissociation from SUR1, producing a short, low-amplitude insulin response and the most modest HbA1c reduction, well matched to predominantly postprandial hyperglycemia
D) It is a biguanide that lowers fasting glucose by suppressing hepatic gluconeogenesis
E) It must be taken at bedtime because its effect peaks 8 to 10 hours after dosing
ANSWER: C
Rationale:
Nateglinide is a phenylalanine derivative meglitinide with an even faster dissociation rate from SUR1 than repaglinide, producing a short, low-amplitude insulin secretory response. Its glucose-lowering efficacy is accordingly the most modest (approximately 0.5 to 0.8 percent HbA1c reduction as monotherapy), and it is particularly suited to patients with predominantly postprandial hyperglycemia and preserved fasting glucose.
Option A: Option A is incorrect because nateglinide is a meglitinide, not a long-acting sulfonylurea, and does not provide 24-hour basal coverage.
Option B: Option B is incorrect because nateglinide binding is rapidly reversible with fast dissociation, the opposite of sustained irreversible binding.
Option D: Option D is incorrect because nateglinide is a secretagogue, not a biguanide acting on hepatic gluconeogenesis.
Option E: Option E is incorrect because nateglinide is taken immediately before each meal to cover the postprandial rise, not at bedtime with a delayed peak.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.